Literature DB >> 30626706

Keeping the balance in NAD metabolism.

Øyvind Strømland1, Marc Niere1, Andrey A Nikiforov2,3, Magali R VanLinden1, Ines Heiland4, Mathias Ziegler5.   

Abstract

Research over the last few decades has extended our understanding of nicotinamide adenine dinucleotide (NAD) from a vital redox carrier to an important signalling molecule that is involved in the regulation of a multitude of fundamental cellular processes. This includes DNA repair, cell cycle regulation, gene expression and calcium signalling, in which NAD is a substrate for several families of regulatory proteins, such as sirtuins and ADP-ribosyltransferases. At the molecular level, NAD-dependent signalling events differ from hydride transfer by cleavage of the dinucleotide into an ADP-ribosyl moiety and nicotinamide. Therefore, non-redox functions of NAD require continuous biosynthesis of the dinucleotide. Maintenance of cellular NAD levels is mainly achieved by nicotinamide salvage, yet a variety of other precursors can be used to sustain cellular NAD levels via different biosynthetic routes. Biosynthesis and consumption of NAD are compartmentalised at the subcellular level, and currently little is known about the generation and role of some of these subcellular NAD pools. Impaired biosynthesis or increased NAD consumption is deleterious and associated with ageing and several pathologies. Insults to neurons lead to depletion of axonal NAD and rapid degeneration, partial rescue can be achieved pharmacologically by administration of specific NAD precursors. Restoring NAD levels by stimulating biosynthesis or through supplementation with precursors also produces beneficial therapeutic effects in several disease models. In this review, we will briefly discuss the most recent achievements and the challenges ahead in this diverse research field.
© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  ADP-ribosylation; NAD(P) metabolism; Wallerian degeneration; cellular localisation; sirtuins

Mesh:

Substances:

Year:  2019        PMID: 30626706     DOI: 10.1042/BST20180417

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  30 in total

1.  Scalable syntheses of traceable ribosylated NAD+ precursors.

Authors:  M V Makarov; N W Harris; M Rodrigues; M E Migaud
Journal:  Org Biomol Chem       Date:  2019-09-20       Impact factor: 3.876

2.  Sirtuin-1 regulates organismal growth by altering feeding behavior and intestinal morphology in planarians.

Authors:  Benjamin Ziman; Peter Karabinis; Paul Barghouth; Néstor J Oviedo
Journal:  J Cell Sci       Date:  2020-05-27       Impact factor: 5.285

Review 3.  The CD38 glycohydrolase and the NAD sink: implications for pathological conditions.

Authors:  Julianna D Zeidler; Kelly A Hogan; Guillermo Agorrody; Thais R Peclat; Sonu Kashyap; Karina S Kanamori; Lilian Sales Gomez; Delaram Z Mazdeh; Gina M Warner; Katie L Thompson; Claudia C S Chini; Eduardo Nunes Chini
Journal:  Am J Physiol Cell Physiol       Date:  2022-02-09       Impact factor: 4.249

4.  Evolution of a histone variant involved in compartmental regulation of NAD metabolism.

Authors:  Iva Guberovic; Sarah Hurtado-Bagès; Ciro Rivera-Casas; Gunnar Knobloch; Roberto Malinverni; Vanesa Valero; Michelle M Leger; Jesús García; Jerome Basquin; Marta Gómez de Cedrón; Marta Frigolé-Vivas; Manjinder S Cheema; Ainhoa Pérez; Juan Ausió; Ana Ramírez de Molina; Xavier Salvatella; Iñaki Ruiz-Trillo; Jose M Eirin-Lopez; Andreas G Ladurner; Marcus Buschbeck
Journal:  Nat Struct Mol Biol       Date:  2021-12-09       Impact factor: 15.369

5.  The NAD+-mitophagy axis in healthy longevity and in artificial intelligence-based clinical applications.

Authors:  Yahyah Aman; Johannes Frank; Sofie Hindkjær Lautrup; Adrian Matysek; Zhangming Niu; Guang Yang; Liu Shi; Linda H Bergersen; Jon Storm-Mathisen; Lene J Rasmussen; Vilhelm A Bohr; Hilde Nilsen; Evandro F Fang
Journal:  Mech Ageing Dev       Date:  2019-12-05       Impact factor: 5.432

6.  Chemical and Biochemical Reactivity of the Reduced Forms of Nicotinamide Riboside.

Authors:  Mikhail V Makarov; Faisal Hayat; Briley Graves; Manoj Sonavane; Edward A Salter; Andrzej Wierzbicki; Natalie R Gassman; Marie E Migaud
Journal:  ACS Chem Biol       Date:  2021-03-30       Impact factor: 5.100

Review 7.  Sirtuin deficiency and the adverse effects of fructose and uric acid synthesis.

Authors:  Bernardo Rodriguez-Iturbe; Richard J Johnson; Miguel A Lanaspa; Takahiko Nakagawa; Fernando E Garcia-Arroyo; Laura G Sánchez-Lozada
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2022-03-10       Impact factor: 3.619

8.  NAD+ metabolism controls growth inhibition by HIF1 in normoxia and determines differential sensitivity of normal and cancer cells.

Authors:  Michal W Luczak; Casey Krawic; Anatoly Zhitkovich
Journal:  Cell Cycle       Date:  2021-08-12       Impact factor: 5.173

9.  Benefits in cardiac function by CD38 suppression: Improvement in NAD+ levels, exercise capacity, heart rate variability and protection against catecholamine-induced ventricular arrhythmias.

Authors:  Guillermo Agorrody; Thais R Peclat; Gonzalo Peluso; Luis A Gonano; Leonardo Santos; Wim van Schooten; Claudia C S Chini; Carlos Escande; Eduardo N Chini; Paola Contreras
Journal:  J Mol Cell Cardiol       Date:  2022-02-01       Impact factor: 5.763

Review 10.  Nicotinamide N-Methyltransferase in Acquisition of Stem Cell Properties and Therapy Resistance in Cancer.

Authors:  Renata Novak Kujundžić; Marin Prpić; Nikola Đaković; Nina Dabelić; Marko Tomljanović; Anamarija Mojzeš; Ana Fröbe; Koraljka Gall Trošelj
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.